Dow Jones
38.705,00 +115,84 (+0,30%) Nasdaq
17.841,15 +152,27 (+0,86%) Nikkei 225
38.102,44 -712,12 (-1,83%) EUR/USD
1,0726 +0,0017 (+0,16%) Bitcoin EUR
61.494,22 -580,17 (-0,93%) CMC Crypto 200
1.380,65 -7,52 (-0,54%)
Conduit Pharmaceuticals Inc. (CDT)
| Chiusura precedente | 1,8000 |
| Aperto | 1,7650 |
| Denaro | 0,0000 x 0 |
| Domanda | 1,6600 x 100 |
| Min-Max giorno | 1,6100 - 1,7699 |
| Intervallo di 52 settimane | 0,9500 - 25,0000 |
| Volume | |
| Media Volume | 37.142 |
| Capitalizzazione | 125,51M |
| Beta (mensile su 5 anni) | 2,44 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0300 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656
Collaboration underscores Conduit’s mission to advance promising treatments by developing assets that have already completed Phase I trialsSAN DIEGO and LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, today announced a partnership with ClinConnect, a first-of-its-kind platform redefining how patien
- GlobeNewswire
Presidio Property Trust Announces Closing of Merger of Its Sponsored SPAC Murphy Canyon Acquisition Corp Now Trading as Conduit Pharmaceuticals (Nasdaq: CDT and CDTTW)
Presidio’s sponsored SPAC completed its previously announced business combination with Conduit Pharmaceuticals, Inc.Conduit now trades on the Nasdaq under ticker symbol “CDT” for its common stock on the Global Market and ticker symbol “CDTTW” for its warrants on the Capital Market SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc., (NASDAQ: SQFT; SQFTP; SQFTW) (“Presidio” or the “Company”), today announced the successful merger with and commencement of trading of Conduit
- GlobeNewswire
Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination
SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited (“Conduit Pharmaceuticals”), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (Nasdaq: MURF) (“MURF”), announced today the completion of the previously announced business combination (the “Transaction”). Conduit expects to commence trading on September 25, 2023, under ticke
